Skip to Main Content

The development of Hematology-Oncology Therapy was originally inspired by the need for a readily accessible, up-to-date, comprehensive therapy resource, supported by referenced literature. The first and second editions received considerable acclaim and filled a void in the medical literature. Over 800 treatment regimens are presented in a concise and uniform format that includes oncologic disorders, non-neoplastic hematologic disorders, and supportive care.

Due to rapid and extensive advances in the field of hematology-oncology, the third edition has significantly expanded and the entire content is now online at AccessHemOnc.com. The online platform created for the third edition will be continually updated, including newly approved regimens.

The four sections of Hematology-Oncology Therapy are:

  1. Cancer regimens (Print & Online)

  2. Antiemetics, Growth Factors, Dose Modification and Drug Preparation (Print & Online)

  3. Supportive Care, Complications, and Screening (Online)

  4. Selected Hematologic Diseases (Online)

Section I provides detailed information about the administration, supportive care, toxicity, dose modification, monitoring, and efficacy of commonly used and recently approved therapeutic regimens. Each chapter is focused on a specific cancer and contains information about epidemiology, pathology, work-up, and staging, as well as survival data. In addition, each chapter has an Expert Opinion section in which experts in the field provide treatment recommendations and guidance on the use of the included regimens. Section II contains chapters on antiemetics, growth factors, and the administration and formulation of anti-cancer drugs. Section III consists of topics commonly encountered in clinical hematology-oncology practice. Section IV provides an authoritative guide to therapy for principal diseases in consultative hematology.

Hematology-Oncology Therapy integrates extensive information that is critical to both office- and hospital-based hematology and oncology clinical practices. This comprehensive approach makes the book invaluable to all practitioners involved in the care of patients with cancer or hematologic diseases and complements other excellent reference books on hematology-oncology.

We wish to express our appreciation to the many contributors to this book, whose expert knowledge in their fields makes Hematology-Oncology Therapy a unique addition to the medical literature. They helped us compile the extensive and detailed therapy information contained in this book, which is a testament to the efforts of so many to improve the treatment of patients with oncologic and hematologic diseases. We are profoundly grateful to our outstanding colleague Gerard Mascara, Oncology Clinical Pharmacy Specialist, for his dedication and untiring efforts in reviewing each treatment regimen and confirming the accuracy of dosage administration and to Melanie S. Norris, PharmD and Jacob E. Winschel, MS, PharmD for their assistance for the treatment regimens.

We also wish to thank our editors, Harriet Lebowitz, Karen Edmonson and Jason Malley, at McGraw Hill for their continued support, patience, and faith in our vision and concept for this book. Their professional support has earned our admiration and gratitude. Finally, we would like to thank those with whom we work and those we love for their support during the writing and editing of the third edition.

Michael M. Boyiadzis, MD, MHSc
Tito Fojo, MD, PhD

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.